Institutional Perspectives in Gastroenterology: Inflammatory Bowel Disease


A group of experts discuss new and emerging therapies for IBD.

A group of experts from the University of North Carolina at Chapel Hill have come together to discuss many crucial topics for the treatment of patients with inflammatory bowel disease (IBD).

The panel was part of HCPLive’s® State of the Science Summit called Institutional Perspectives in Gastroenterology: Inflammatory Bowel Disease.

Leading the group was Millie Long, MD, MPH. Joining Long was Kimberly Weaver, MD, Edward Barnes, MD, MPH, and Hans Herfarth, MD, PhD.

The program began with Weaver’s discussion on managing IBD during COVID-19. Weaver’s discussion was followed by Barnes talking about the early use of biologics and Herfarth’s explainer on newly approved and emerging therapies in IBD.

Long closed out the event with a talk about taking a treat to target approach in IBD.

Related Videos
Adam Faye, MD: Treating the Older Population With IBD
Jordan Axelrad, MD: Assessing the Risk of Cancer for IBD Patients
Jan Wehkamp, MD: Promising New Guselkumab Data From DDW 2023
Taha Qazi, MD: Improving the Quality of Life for Patients Following Pouch Surgery
Jessica Allegretti, MD, MPH: An Update on the Quasar Study at DDW 2023
Sunanda Kane, MD: The Role of Small Molecule Therapies in IBD
Nisha Thacker: The Western Diet and Pediatric IBD
Jordan Axelrad, MD: The Emergence of Biosimilars in Gastroenterology
© 2023 MJH Life Sciences

All rights reserved.